How big is the Ornithine Transcarbamylase Deficiency Treatment Market?

The Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.82 billion in 2024 and grow at a CAGR of 4.30% to reach USD 1.01 billion by 2029. Read More

What is the current Ornithine Transcarbamylase Deficiency Treatment Market size?

In 2024, the Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.82 billion. Read More

Who are the key players in Ornithine Transcarbamylase Deficiency Treatment Market?

Amgen Inc. (Horizon Therapeutics plc), Bausch Health Companies Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc. and Zevra Therapeutics (Acer Therapeutics) are the major companies operating in the Ornithine Transcarbamylase Deficiency Treatment Market. Read More

Which is the fastest growing region in Ornithine Transcarbamylase Deficiency Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Ornithine Transcarbamylase Deficiency Treatment Market?

In 2024, the North America accounts for the largest market share in Ornithine Transcarbamylase Deficiency Treatment Market. Read More

What years does this Ornithine Transcarbamylase Deficiency Treatment Market cover, and what was the market size in 2023?

In 2023, the Ornithine Transcarbamylase Deficiency Treatment Market size was estimated at USD 0.78 billion. The report covers the Ornithine Transcarbamylase Deficiency Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Ornithine Transcarbamylase Deficiency Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Ornithine Transcarbamylase (OTC) Deficiency Treatment Companies

This report lists the top Ornithine Transcarbamylase (OTC) Deficiency Treatment companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Ornithine Transcarbamylase (OTC) Deficiency Treatment industry.